Stock GLSH.Q GELESIS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Gelesis Holdings, Inc.

Gelesis Holdings, Inc. Stock price

Equities

GLSH.Q

US36850R2040

Pharmaceuticals

End-of-day quote OTC Markets
Other stock markets
 06:00:00 2023-12-06 pm EST 		Intraday chart for Gelesis Holdings, Inc. 5-day change 1st Jan Change
0.0015 USD -4.46% -50.00% -99.48%
Oct. 30 Gelesis Holdings, Inc. Filed for Bankruptcy CI
Oct. 12 PureTech Health plc cancelled the acquisition of the remaining 76.7% stake in Gelesis Holdings, Inc. from Pacific Investment Management Company LLC, Hpso Spv Limited, SSD2 LLC, Cms Medical Venture Investment (HK) Limited and others. CI

Financials (USD)

Sales 2022 25.77 Sales 2023 * - Capitalization 21.21M
Net income 2022 -55M Net income 2023 * - EV / Sales 2022
2 951 835x
Net Debt 2022 54.85M Net cash position 2023 * - EV / Sales 2023 * -
P/E ratio 2022
-0,21x
P/E ratio 2023 *
Employees 93
Yield 2022
-
Yield 2023 *
-
Free-Float 47.3%
More Fundamentals * Assessed data

Chart Gelesis Holdings, Inc.

Dynamic Chart

Latest news about Gelesis Holdings, Inc.

Gelesis Holdings, Inc. Filed for Bankruptcy CI
PureTech Health plc cancelled the acquisition of the remaining 76.7% stake in Gelesis Holdings, Inc. from Pacific Investment Management Company LLC, Hpso Spv Limited, SSD2 LLC, Cms Medical Venture Investment (HK) Limited and others. CI
Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Interim Principal Financial Officer CI
Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Chief Compliance Officer, Corporate Secretary, Treasurer, Principal Accounting Officer CI
Gelesis Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Orgenesis Names Elliot Maltz Chief Financial Officer MT
Elliot Maltz, the Chief Financial Officer of Gelesis Holdings, Inc. Resigns, Effective August 15, 2023 CI
Elliot Maltz, Treasurer, Chief Compliance Officer and Corporate Secretary (And Principal Financial and Accounting Officer) of Gelesis Holdings, Inc. Resigns from All Positions, Effective August 15, 2023 CI
Gelesis Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Gelesis Holdings, Inc. announced that it has received $2 million in funding from PureTech Health LLC CI
Gelesis Holdings, Inc. Announces Board Changes CI
Gelesis Holdings, Inc. Announces Resignation of Dominic Perks as Class I Director CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from S&P TMI Index CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell 2500 Value-Dynamic Index CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell 2500 Growth-Dynamic Index CI
More news

Analyst Recommendations on Gelesis Holdings, Inc.

Citigroup Starts Gelesis Holdings at Neutral With $1.15 Price Target MT
More recommendations

Press releases Gelesis Holdings, Inc.

Gelesis : Bankruptcy - Form 8-K PU
GELESIS HOLDINGS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) AQ
GELESIS HOLDINGS, INC. : Regulation FD Disclosure (form 8-K) AQ
GELESIS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) AQ
Gelesis Reports Fourth Quarter and Full Year 2022 Results BU
More press releases

News in other languages on Gelesis Holdings, Inc.

Gelesis : leve seulement 105 millions de dollars sur les 376 millions prévus
Planète Bourse : La revue de presse du vendredi 8 avril 2022
Gelesis® annuncia i risultati preliminari del lancio nazionale di Plenity®: livelli record di prescrizioni e del traffico online
Gelesis® publiceert voorlopige nationale lanceringsresultaten voor Plenity®, recordniveaus van recepten en online verkeer
Gelesis® veröffentlicht vorläufige landesweite Markteinführungsergebnisse für Plenity®: Rekordverdächtige Verschreibungszahlen und Online-Verkehr
More news

Quotes and Performance

1 day-4.46%
1 week-50.00%
Current month-50.00%
1 month+36.36%
3 months-96.34%
6 months-86.36%
Current year-99.48%
More quotes

Highs and lows

1 week
0.00
Extreme 0.001
0.00
1 month
0.00
Extreme 0.001
0.00
Current year
0.00
Extreme 0.0003
0.54
1 year
0.00
Extreme 0.0003
0.54
3 years
0.00
Extreme 0.0003
12.23
5 years
0.00
Extreme 0.0003
12.23
10 years
0.00
Extreme 0.0003
12.23
More quotes

Managers and Directors - Gelesis Holdings, Inc.

Managers TitleAgeSince
Yishai Zohar CEO
 Chief Executive Officer 60 2022
David Pass COO
 Chief Operating Officer 55 2022
Elaine Chiquette CTO
 Chief Tech/Sci/R&D Officer 57 2022
Members of the board TitleAgeSince
Yishai Zohar CEO
 Chief Executive Officer 60 2022
Paul R. Fonteyne BRD
 Director/Board Member 62 2022
Clayton Christopher BRD
 Director/Board Member 50 2022
More insiders

ETFs positioned on Gelesis Holdings, Inc.

Name Weight AuM 1st Jan change Investor Rating
VANGUARD TOTAL STOCK MARKET ETF - USD ETF Vanguard Total Stock Market ETF - USD
0.00% 281,588 M€ +19.13%
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD ETF Adaptive RH Hedged Multi-Asset Income ETF - USD
0.00% 31 M€ -3.03% -
More ETFs positioned on Gelesis Holdings, Inc.

Quotes

Date Price Change Volume
23-12-07 0.0015 -4.46% 3,572
23-12-06 0.00157 +57.00% 64,945
23-12-05 0.001 0.00% 1,074
23-12-04 0.001 -66.67% 3,284
23-11-30 0.003 +200.00% 56,673

End-of-day quote OTC Markets, December 06, 2023

More quotes

Company Profile

Gelesis Holdings, Inc. is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).
Sector
Pharmaceuticals
Calendar
2024-03-20 - Q4 2023 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GELESIS HOLDINGS, INC. Stock Gelesis Holdings, Inc.
-99.48% 110 002 $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.80% 529 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.15% 430 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-12.03% 374 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-6.37% 263 B $
ABBVIE INC. Stock AbbVie Inc.
-8.44% 261 B $
NOVARTIS AG Stock Novartis AG
+0.68% 198 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-9.98% 197 B $
PFIZER, INC. Stock Pfizer, Inc.
-44.13% 162 B $
AMGEN INC. Stock Amgen Inc.
+3.30% 145 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Gelesis Holdings, Inc. - OTC Markets
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer